Scope and Methodology
Reasons for Advanced Drug Delivery Systems
Phases of Drug Action
Liposome Drug Delivery
Polymer Drug Delivery
Nano- and Microparticulates
Monoclonal Antibodies Drug Delivery
Chapter Three: Trends and Developments
Expansion of Biotechnology
Incorporation of Technology
Molecular Imprinted Polymers
Pharmacoeconomics of Drug Delivery Systems
Gene Therapy Drug Delivery
Antisense Delivery Systems
Thermosetting Biodegradable Polymer
Triggerable Drug Delivery
VP22 Drug Delivery
Prodrug Drug Delivery
Single Chain Antigen-Binding Protein Technology
Magnetic Targeted Carriers
Heat Shock Protein Technology
Other Emerging Drug Delivery Technologies
Chapter Four: Market Size and Growth
Chapter Five: Competitive and Market Analysis
Chapter Six: Company Profiles
Atrix Laboratories, Inc.
Control Delivery Systems, Inc.
Elan Corporation, Plc
EnColl Corporation, Inc.
Gilead Sciences, Inc.
Guilford Pharmaceuticals, Inc.
IDEC Pharmaceuticals Corporation
Protein Design Labs, Inc.
Appendix: Company Directory
List of Exhibits
Table 2-1: Sequence of Drug Action
Table 2-2: Marketed Monoclonal Antibodies, 2000
Table 4-1: The Worldwide Market for Advanced Drug Delivery
Systems by Type, 1995-2005
Table 4-2: The Worldwide Market for Advanced Drug Delivery Systems,
Market Share by Type, 1995-2005
Table 4-3: The Worldwide Market for Advanced Drug Delivery Systems by Pharmaceutical and Drug Delivery Component, 1995-2005
Table 4-4: The Worldwide Market for Advanced Drug Delivery Systems, Distribution of Revenue by Pharmaceutical and Drug Delivery Component, 1995-2005
Table 5-1: Worldwide Market for Advanced Drug Delivery System,
Revenues and Market Share by Supplier, 2000
Figure 4-1: The Worldwide Market for Advanced Drug Delivery Systems,
Revenues by Type, 1995-2005
Figure 4-2: The Worldwide Market for Advanced Drug Delivery Systems,
Share by Type, 2000
Figure 4-3: The Worldwide Market for Advanced Drug Delivery Systems,
Share by Type, 2005
Figure 4-4: The Worldwide Market for Advanced Drug Delivery Systems, Distribution of Revenue by Pharmaceutical and Drug Delivery Component, 1995-2005
Figure 4-5: The Worldwide Market for Advanced Drug Delivery Systems, Distribution of Revenue by Pharmaceutical and Drug Delivery Component, 2000
Figure 4-6: The Worldwide Market for Advanced Drug Delivery Systems, Distribution of Revenue by Pharmaceutical and Drug Delivery Component, 2005
Figure 5-1: Worldwide Market for Advanced Drug Delivery Systems,
Market Share by Leading Supplier, 2000
Drug Delivery Series: The Market for Advanced Drug Delivery Technology Systems: Volume 5 Description
Drug Delivery Series: The Market for Advanced Drug Delivery Technology Systems: Volume 5
Volume 5 of the Drug Delivery Series will address advanced drug delivery technologies, including such cutting edge technology as liposome drug delivery, polymer and polymeric micelles, micro-particulates, DNA binding, monoclonal antibodies, gene therapy and micro-encapsulation. Emerging technologies are continuing to bring many developmental advances to the pharmaceutical industry.
The Drug Delivery Series
An Innovative NEW Series of Five Reports, Featuring
Primary Research & Global Coverage
Drug delivery is one of the most important drivers in the rapidly changing pharmaceutical industry. Each volume of this new series examines an area of drug delivery singly and in depth. Market opportunities, new technologies and products, shifting alliances and licensing deals, important trends, and forecasts through 2005 are covered in each of the five volumes of the series.
Kalorama’s analysts have taken a unique look at the market today and in the future by calculating not only total market size and growth, but also the relative value of the drug delivery component itself as separate from total pharmaceutical sales. This quantitative analysis is extremely instructive and unique to this series of reports.
Anyone involved in the pharmaceutical industry—drug delivery
companies or pharmaceutical manufacturers—can turn to this series to examine competitors, extend product life cycles, and learn more about the plethora of advanced drug delivery systems in development that will suit currently available products.
For each of the major delivery routes, the series covers:
Market size, segmentation, and growth
Market drivers, barriers, and trends
Competitive analysis of companies and products—both
current and in development
Value of drug delivery technology in relation to
Impact of delivery technology on the viability of new
Implications for pharmaceutical sales and marketing
Profiles of the major players, including partnerships and alliances
International directory of companies involved in the segment
Use These Valuable Reports to:
Define and size your target market
Capitalize on industry trends
Reduce the risk of your business investment
Position yourself against your competition
Effectively launch new products or enter new markets
Create successful marketing and sales strategies
Create highly-targeted marketing messages
Strengthen brand awareness
Identify new revenue opportunities
Empower your sales force with the tools they need to succeed
Advance Drug Delivery to Top $7 Billion in Revenues
New York, February 27, 2002 /PR Newswire — The market for drugs employing advanced drug delivery technologies is expanding rapidly and will surpass $7 billion by 2005, according to a new study released today from Kalorama Information and available at MarketResearch.com. The segment has seen double-digit growth over the past few years, and the study found that this trend should continue.
Moreover, the study entitled The Market for Advance Drug Delivery Systems, reveals that revenues attributable to the delivery technologies themselves, separate from those attributable to the pharmaceutical component sales, are gaining ground faster than the segment as a whole. In an analysis unique to Kalorama, the study shows that the relative value of advanced delivery technologies will approach half of the total market value by 2005.
“There appear to be several factors driving the expansion,” states Steven Heffner, acquisitions editor at Kalorama Information. “Among them are the growing number of difficult-to-administer biopharmaceuticals, pharma’s ever-increasing demand for sophisticated life-cycle management, and the age-old catchall—because the technologies are there.”
The Market for Advance Drug Delivery Systems is the final volume in a five-volume study of drug delivery technologies conducted over the past year. In addition to the main technologies covered—liposomal, monoclonal antibody-based, and polymer-based technologies—the current report discusses developments in a whole host of newer technologies such as nanoparticles, molecular imprinted polymers, matallofullerenes, prodrug delivery, and others. Other volumes in the series examine oral, injectable and implantable, pulmonary, and transdermal and transmucosal delivery.